VA adviser pushes to expand psychedelic therapy access for up to 2.1 million veterans

VA senior adviser Andrew Gradison wants capacity to offer psychedelic therapy to as many as 2.1 million veterans.

Objective Facts

Andrew Gradison, a senior adviser at the Veterans Health Administration, said at the Psychedelic Healthcare Forum in New York that the VA wants to build capacity to offer psychedelic therapies to as many as 2.1 million veterans with PTSD or depression, Politico and Psychedelic Alpha reported. That group is drawn from the 6.4 million veterans who regularly use VA care. Gradison said the VA has chosen ten sites, would start treating patients right away if drugs win FDA approval early next year, and expects demand to outrun supply. No psychedelic drug has been approved by the FDA for a mental illness, and Compass Pathways has said it expects a decision on its psilocybin therapy in the first half of 2027, according to Politico. Nocut News in South Korea carried the story mainly as a veteran suicide and regulation story.

Deep Dive

Gradison's remarks build on a string of federal moves this year. Donald Trump signed an executive order in April directing faster review of psychedelic drugs, including ibogaine, the Associated Press reported. In July the VA and HHS signed a memorandum of understanding to coordinate trials and train clinicians to give psychedelic medications if they are approved, according to Military Times. In August the VA opened a five-site psilocybin trial for treatment-resistant depression, The American Legion reported. VA Secretary Doug Collins has framed these steps as turning research into treatment. The 2.1 million figure describes eligibility, not near-term reach. Psychedelic Alpha reported that Gradison expects the first year to be a challenge even at roughly a thousand patients, and Politico quoted him saying demand will exceed supply. The FDA rejected MDMA-assisted therapy for PTSD in 2024, and the AP noted that ibogaine carries a risk of potentially fatal heart problems. Kyleanne Hunter of Iraq and Afghanistan Veterans of America told The National News Desk in July that rigorous trials are needed to measure risks as well as benefits, and that most evidence comes from former special operations troops. Support in Congress has come from both parties: Politico quoted Rep. Lou Correa, a Democrat, and Rep. Morgan Luttrell, a Republican who wants the executive order written into law. The next marker is the FDA. Gradison said the VA would begin treating patients if drugs become available in January or February, and Politico reported that Compass Pathways expects a psilocybin decision in the first half of 2027. Watch whether the VA names its ten sites, how it trains therapists to deliver treatment alongside psychotherapy, and whether Congress acts on Luttrell's push to codify the order after he retires in January.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

VA adviser pushes to expand psychedelic therapy access for up to 2.1 million veterans

VA senior adviser Andrew Gradison wants capacity to offer psychedelic therapy to as many as 2.1 million veterans.

Oct 26, 2026· Updated Oct 27, 2026
What's Going On
  • Andrew Gradison, a senior adviser at the Veterans Health Administration, told a psychedelics conference in New York that the VA wants to expand capacity to treat up to 2.1 million veterans, according to Politico reporter Amanda Friedman and Psychedelic Alpha.
  • Psychedelic Alpha reported that the 2.1 million figure covers veterans with PTSD, major depressive disorder or treatment-resistant depression among the 6.4 million who get regular VA care.
  • Gradison said the VA has picked ten sites it would not name and expects to treat only about four digits' worth of patients in the first year, Psychedelic Alpha reported.
  • No federal regulator has found psychedelics safe or effective for mental illness, a point Politico's report and Just Security's October 26 Early Edition both made.
  • South Korea's Nocut News relayed the Politico report to Korean readers, focusing on veteran suicide figures and the lack of regulatory approval.
◆ All Sources (9)
Psychedelic Alpha - Ten VA Sites, REMS and Ibogaine's "Uphill Battle": Feds Weigh In on Psychedelic AccessJust A Dude With Thoughts (Substack repost of Politico) - The Trump administration moves to treat millions of mentally ill veterans with psychedelicsJust Security - Early Edition: October 26, 2026Associated Press via 6abc - Trump signs order to speed review of psychedelics, including the controversial drug ibogaineMilitary Times - VA, HHS to increase psychedelic therapy research for PTSD, military-related mental health issuesKOMO News (The National News Desk) - VA, HHS act on Trump's order to speed psychedelic drug researchThe American Legion - VA launches psilocybin trial for veterans with treatment-resistant depressionJoe.My.God. - WH Moves To Treat Veterans With PsychedelicsNocut News - U.S. Government Pushes Psychedelic Therapy for Veterans
Objective Deep Dive

Gradison's remarks build on a string of federal moves this year. Donald Trump signed an executive order in April directing faster review of psychedelic drugs, including ibogaine, the Associated Press reported. In July the VA and HHS signed a memorandum of understanding to coordinate trials and train clinicians to give psychedelic medications if they are approved, according to Military Times. In August the VA opened a five-site psilocybin trial for treatment-resistant depression, The American Legion reported. VA Secretary Doug Collins has framed these steps as turning research into treatment.

The 2.1 million figure describes eligibility, not near-term reach. Psychedelic Alpha reported that Gradison expects the first year to be a challenge even at roughly a thousand patients, and Politico quoted him saying demand will exceed supply. The FDA rejected MDMA-assisted therapy for PTSD in 2024, and the AP noted that ibogaine carries a risk of potentially fatal heart problems. Kyleanne Hunter of Iraq and Afghanistan Veterans of America told The National News Desk in July that rigorous trials are needed to measure risks as well as benefits, and that most evidence comes from former special operations troops. Support in Congress has come from both parties: Politico quoted Rep. Lou Correa, a Democrat, and Rep. Morgan Luttrell, a Republican who wants the executive order written into law.

The next marker is the FDA. Gradison said the VA would begin treating patients if drugs become available in January or February, and Politico reported that Compass Pathways expects a psilocybin decision in the first half of 2027. Watch whether the VA names its ten sites, how it trains therapists to deliver treatment alongside psychotherapy, and whether Congress acts on Luttrell's push to codify the order after he retires in January.

◈ Tone Comparison

Coverage of Gradison's remarks did not split along partisan lines in the reporting found. Psychedelic Alpha wrote in the dry language of a trade publication, while Politico's Amanda Friedman paired Gradison's numbers with the caution that no regulator has backed the drugs for mental illness. The left-leaning blog Joe.My.God. added little analysis and instead pointed readers to Gradison's earlier remarks on sex education.